NDATOPICALCREAMPriority Review
Approved
Nov 1952
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BENOQUIN (monobenzone) is a topical cream approved in 1952 for depigmentation therapy. It is used to treat vitiligo and other hyperpigmentation disorders by inhibiting melanin production in the skin. The product represents a legacy small-molecule dermatological treatment with a narrow but persistent patient population.
LOE Approaching
Legacy product approaching loss of exclusivity with minimal linked commercial roles; team likely focused on managed care and niche market defense rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BENOQUIN offers limited upside career movement but stable, specialized expertise in legacy dermatology product management and niche market dynamics. This role suits professionals seeking operational continuity and managed-care expertise in a low-growth, high-margin therapeutic area rather than innovation or commercial scaling.
Product ManagerRegional Sales Manager
Worked on BENOQUIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.